FDA Import Refusal 799-8972052-1/10003/1 — Boehringer Ingelheim Canada
The FDA refused shipment 799-8972052-1/10003/1 from Boehringer Ingelheim Canada (Canada) on Jan 21, 2026. The refused product falls under Drugs and Biologics — EMPAGLIFLOZIN (ANTI-DIABETIC). Cited charges: 118,75 This firm has 5 or more other import refusals on record.
Refusal details
- Date
- Jan 21, 2026
- Country
- Canada
- Product Category
- Drugs and Biologics
- Product Code
- 61PCY73 EMPAGLIFLOZIN (ANTI-DIABETIC)
- Charges
- 118,75